Susannah Gray - Net Worth and Insider Trading

Susannah Gray Net Worth

The estimated net worth of Susannah Gray is at least $340,816 dollars as of 2024-05-15. Susannah Gray is the Director of Maravai LifeSciences Holdings Inc and owns about 31,852 shares of Maravai LifeSciences Holdings Inc (MRVI) stock worth over $340,816. Details can be seen in Susannah Gray's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Susannah Gray has not made any transactions after 2020-11-24 and currently still holds the listed stock(s).

Transaction Summary of Susannah Gray

To

Susannah Gray Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Susannah Gray owns 4 companies in total, including 4D Molecular Therapeutics Inc (FDMT) , Morphic Holding Inc (MORF) , and Maravai LifeSciences Holdings Inc (MRVI) among others .

Click here to see the complete history of Susannah Gray’s form 4 insider trades.

Insider Ownership Summary of Susannah Gray

Ticker Comapny Transaction Date Type of Owner
FDMT 4D Molecular Therapeutics Inc 2020-12-10 director
MORF Morphic Holding Inc 2021-04-27 director
MRVI Maravai LifeSciences Holdings Inc 2020-11-24 director
2023-02-26 director

Susannah Gray Latest Holdings Summary

Susannah Gray currently owns a total of 1 stock. Susannah Gray owns 31,852 shares of Maravai LifeSciences Holdings Inc (MRVI) as of November 24, 2020, with a value of $340,816.

Latest Holdings of Susannah Gray

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
MRVI Maravai LifeSciences Holdings Inc 2020-11-24 31,852 10.70 340,816

Holding Weightings of Susannah Gray


Susannah Gray Form 4 Trading Tracker

According to the SEC Form 4 filings, Susannah Gray has made a total of 1 transactions in Maravai LifeSciences Holdings Inc (MRVI) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Maravai LifeSciences Holdings Inc is the acquisition of 20,000 shares on November 24, 2020, which cost Susannah Gray around $540,000.

Insider Trading History of Susannah Gray

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Susannah Gray Trading Performance

GuruFocus tracks the stock performance after each of Susannah Gray's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Susannah Gray is 27.5%. GuruFocus also compares Susannah Gray's trading performance to market benchmark return within the same time period. The performance of stocks bought by Susannah Gray within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Susannah Gray's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Susannah Gray

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 13.01
Relative Return to S&P 500(%) 11.15

Susannah Gray Ownership Network

Ownership Network List of Susannah Gray

No Data

Ownership Network Relation of Susannah Gray


Susannah Gray Owned Company Details

What does 4D Molecular Therapeutics Inc do?

Who are the key executives at 4D Molecular Therapeutics Inc?

Susannah Gray is the director of 4D Molecular Therapeutics Inc. Other key executives at 4D Molecular Therapeutics Inc include Chief Legal and HR Officer Scott Bizily , director & Chief Executive Officer David Kirn , and Chief Medical Officer Robert Young Kim .

4D Molecular Therapeutics Inc (FDMT) Insider Trades Summary

Over the past 18 months, Susannah Gray made no insider transaction in 4D Molecular Therapeutics Inc (FDMT). Other recent insider transactions involving 4D Molecular Therapeutics Inc (FDMT) include a net sale of 39,387 shares made by Scott Bizily , a net sale of 340,847 shares made by David Kirn , and a net purchase of 310,000 shares made by Viking Global Investors Lp .

In summary, during the past 3 months, insiders sold 21,145 shares of 4D Molecular Therapeutics Inc (FDMT) in total and bought 0 shares, with a net sale of 21,145 shares. During the past 18 months, 949,786 shares of 4D Molecular Therapeutics Inc (FDMT) were sold and 850,000 shares were bought by its insiders, resulting in a net sale of 99,786 shares.

4D Molecular Therapeutics Inc (FDMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

4D Molecular Therapeutics Inc Insider Transactions

No Available Data

Susannah Gray Mailing Address

Above is the net worth, insider trading, and ownership report for Susannah Gray. You might contact Susannah Gray via mailing address: 10770 Wateridge Circle Suite 200, San Diego Ca 92121.

Discussions on Susannah Gray

No discussions yet.